Evaluation and Management of Pulmonary Hypertension in ...
pulmonary hypertension and portal hypertension :: Article Creator Merck's Hypertension Drug Receives US FDA's Priority Review Sept 28 (Reuters) - Merck said on Thursday the U.S. Food and Drug Administration (FDA) has accepted under priority review the company's application for an experimental drug to treat pulmonary arterial hypertension in adults. (Reporting by Mariam Sunny in Bengaluru; Editing by Sriraj Kalluvila) Merck Gets FDA Priority Review Of Sotatercept In Pulmonary Arterial Hypertension >MRK By Colin Kellaher Merck & Co. Has won U.S. Food and Drug Administration priority review of its sotatercept drug candidate for the treatment of adults with pulmonary arterial hypertension. The Rahway, N.J., drugmaker said sotatercept, an activin signaling inhibitor, would be the first in its class if approved, bringing a new approach to address the rare and progressive disease of the pulmonary arteries. The FDA grants priori...